MedTrace Logo

Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury

NCT05435235 · Status: SUSPENDED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2024-07-31

No results posted yet for this study

Summary

To compare the incidence of acute kidney injury (AKI) post percutaneous coronary intervention (PCI) in a Dapagliflozin treated group versus a group managed with the usual standard of care.

Conditions

Interventions

DRUG

Dapagliflozin 10mg Tab

One tablet daily starting 48h prior to PCI and continuing for 48h post-PCI.

Sponsors & Collaborators

  • Albert Einstein Healthcare Network

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2025-06-30
Completion
2025-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05435235 on ClinicalTrials.gov